About Ico Therapeutics
iCo Therapeutics Inc. (iCo) is a Canada-based biotechnology company principally focused on the identification, development and commercialization of drug candidates to treat sight-and life-threatening diseases. The Company principally focuses on in-licensing drug candidates with a clinical history, and re-dose, reformulate and develop drug candidates for the treatment of sight-and life-threatening diseases. The Company's product candidates include iCo-007, iCo-008 and an Oral AmpB Delivery System. The Company has initiated Phase II clinical trial for iCo-007. iCo-008 is a human monoclonal antibody that is offered to treat sight threatening forms of allergic conjunctivitis by neutralizing eotaxin-1, a ligand to the chemokine receptor CCR3. Oral AmpB Delivery System is a toxic option for the treatment of serious systemic fungal infections. The Company has completed pre-clinical studies for iCo's Oral AmpB Delivery System.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: N/A
- Sub-Industry: N/A
- Exchange: OTCMKTS
- Symbol: ICOTF
- CUSIP:
Key Metrics:
- Previous Close: $0.00
- 50 Day Moving Average: $
- 200 Day Moving Average: $
- 52-Week Range: $84,457,000.00 - $0.01
- Trailing P/E Ratio:
- P/E Growth:
- Market Cap: $
- Outstanding Shares: 84,457,000
- Beta: 1.51
Profitability:- Return on Equity: -46.43%
- Return on Assets: -45.36%
Debt:- Current Ratio: 42.80%
- Quick Ratio: 42.80%
Additional Links:
Companies Related to Ico Therapeutics:
Consensus Ratings for Ico Therapeutics (OTCMKTS:ICOTF) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.| Ratings Breakdown: | No ratings tracked in the last 12 months. |
| Consensus Rating: | N/A (Score: NaN) |
| Consensus Price Target: | N/A |
Analysts' Ratings History for Ico Therapeutics (OTCMKTS:ICOTF)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Ico Therapeutics (OTCMKTS:ICOTF)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 9/2/2014 | | ($0.01) | ($0.01) | | | View | N/A |  |
| 5/30/2014 | | ($0.02) | ($0.01) | | | View | N/A | |
| 4/28/2014 | | ($0.02) | ($0.02) | | | View | N/A | |
| 11/27/2013 | Q3 | | ($0.01) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Ico Therapeutics (OTCMKTS:ICOTF)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Ico Therapeutics (OTCMKTS:ICOTF)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Ico Therapeutics (OTCMKTS:ICOTF)
No insider trades for this company have been tracked by MarketBeat.com
Latest Headlines for Ico Therapeutics (OTCMKTS:ICOTF)
Ico Therapeutics (OTCMKTS:ICOTF) Chart for Tuesday, September, 27, 2016
